TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of adverse drug reactions/serious adverse drug reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Self-reported psychological general well-being index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to intubate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Severity of Facial Acne
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Severity of Post Inflammatory Hyperpigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percent Change in Weekly Heartburn Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Frequency of Agitated and Aggressive Behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total calcification score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nine Hole Peg Test (NHPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Box and Block Test (BBT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ABILHAND questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Area-under-the-concentration curve (AUC) of rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of ovulating patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Food frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Meal frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Infant and child feeding index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Household spending
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean Percent Change in Spastic Catch Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Acute Rejection
Endpoint domain: Adverse events/effects
Primary endpoint: Overall Incidence Rate of Herpes Zoster Cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: NRG-1 plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in physical withdrawal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in psychological withdrawal symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants Deemed Feasible to Receive Intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Late Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: System Comfort Validation Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unilateral Function Validation Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Function & Robustness Validation Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sputum cell ascorbate and alpha-tocopherol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fusion Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prenatal Attachment Inventory (PAI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Revised Prenatal Distress Questionnaire (NuPDQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Laxation within 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean difference in total operating room time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Gastroparesis Cardinal Symptom index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in blood LDL-cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of serious fall-related injuries
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of all injurious falls
Endpoint domain: Adverse events/effects
Primary endpoint: Vanderbilt ADHD Diagnostic Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Swanson, Nolan and Pelham (SNAP) Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADHA ADHD Rating Scale IV (Home version)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arm Function in Multiple Sclerosis
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Template use at 12 months
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in PANSS-positive and negative syndrome scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in healing quality index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline of Visual Analog Pain Scale at 3 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Maximum Pain Score at 9 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in 24 hr blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum tolerated dose of IV pegaspargase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended Phase 2 dose of pegaspargase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Actigraphy
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Brief Pain Inventory-Intensity
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Change in the CRS-R scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apgar score at one minute of life of the neonate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apgar score at five minutes of life of the neonate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of fetal heart rate abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hunger and satiety feelings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change in ADL
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in NIH RTF Impact Score - stage 1 treatment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in NIH RTF Impact Score - stage 2 treatment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Safety and tolerability of RTA 402
Endpoint domain: Adverse events/effects
Primary endpoint: Cardiovascular Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of Participants With Platelet Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants With a Best Overall Response (OR) of Complete Response (CR) or Partial Response (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Duration of Objective Response (DOR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants With CR at End of Treatment (EOT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Drug related toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Time to Resolution of Lymphopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Adverse Events (AEs) in the Blood and Lymphatic System Disorders SOC
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change in Turesky Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experienced On-treatment Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experienced On-treatment Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of ovulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Efficacy of single food elimination diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to ST Depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Exercise Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in levels of biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Echocardiographical parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Assessment of perfusion and endothelium function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical Disease Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived Efficacy in Patient-Physician Interactions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Block success rate at 30 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Criterion task
Endpoint domain: General outcomes
Primary endpoint: Reduction or Absence of Rejection Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: incidence of leak
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics after single oral dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics after 7 days of oral daily doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of AEB071
Endpoint domain: Adverse events/effects
Primary endpoint: Median Maximal Drug Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-month postoperative knee function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Adverse Events (AEs) and Serious AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With AEs Leading to Premature Discontinuation of Investigational Medicinal Products (IMPs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Left Ventricular Ejection Fraction (LVEF) Below 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients with persistent symptoms after recovery of acute COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number (percentage) of patients with underlying heart conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Agreement in electrocardiogram findings between device A and device B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ankle drawer test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of participants with local nasal events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with increment in the haematological and biochemistry parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from Baseline Systolic Blood Pressure after each intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain during daily activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Vessel Segments Visualized With Diagnostic Quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Upper airway collapsability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Negative expiratory pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Snore
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Grade III or IV alopecia
Endpoint domain: Adverse events/effects
Primary endpoint: Composite of cardiac death or myocardial infarction (MI)
Endpoint domain: Mortality/survival
Primary endpoint: Standard alcohol units consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: length of the clitoris
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Adverse Clinical Events Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Platelet function measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Sickness leave
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Agreement between patient and provider assessment of work of breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Expression of IFNγ and Interleukin-12 (IL-12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Manipulation time Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Manipulation Displacement Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Manipulation Mean Velocity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Manipulation Maximal Velocity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Manipulation Mean Acceleration Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Manipulation Maximal Acceleration Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Restoration of fecal microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of participants with type IA Endoleaks
Endpoint domain: Adverse events/effects
Primary endpoint: Respiratory mechanics index:PEEPi
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Welch Emotional Connection Screen (WECS) Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Correlation of Thoracic Impedance With Ultra-filtration Volume (UFV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of pubertal advancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean SKAMP Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoke-free Days
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Professional Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Coping Orientation to Problems Experienced
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Volume of alveolar ridge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vascular abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: memory lapse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Genetic data analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in score on Beck Depression Inventory - II
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 1-year Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Change in relationship satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in sexual satisfaction/distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in neurocognitive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Typical quantity of alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms of alcohol abuse, dependence and alcohol use disorder
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients hospitalized due to COPD worsening
Endpoint domain: Adverse events/effects
Primary endpoint: Overactive bladder quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) at Day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) at Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment Emergent Ocular Adverse Events (AEs) at Stage I
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Treatment Emergent Ocular Adverse Events (AEs) at Stage II
Endpoint domain: Adverse events/effects
Primary endpoint: ADAS-Cog Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Compliance with nutritional recommendations
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pharmacokinetics of TCZ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacodynamic responses of CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abdominal distribution of visceral fat versus subcutaneous fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in total brain volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in grey matter volume in the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in white matter volume in the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in the volume of brain structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Partial Response of Hemangioma Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration area under the curve 0-t of pyrophosphate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal concentration of pyrophosphate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timepoint of maximal pyrophosphate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to initiation of reperfusion therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic parameters of BAF312
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of deep neuromuscular block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: locoregional progression free survival
Endpoint domain: Mortality/survival
Primary endpoint: CSF BDNF Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evidence of decolonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Vasoactive hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Sustained Virological Response at Week 12 (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Became Afebrile Within 72 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Reported Dose Limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Anti-tumor Responses as Defined by a Decline in PSA of > 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Response Proportion as Defined by a Decline in PSA of > 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of patients receiving inappropriate or inadequate VTE prophylaxis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Grade of endolymphatic hydrops (EH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in negative consequences from drinking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in HIV testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain on VAS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OCT retinal structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintain or lower body mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants With Response of Very Convenient or Somewhat Convenient
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Chest wall pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary Toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes